![PDF] Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/70bc1a06a730e1f512f80dac37d33d6c52a1670a/5-TableI-1.png "PDF] Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. | Semantic Scholar")
PDF] Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. | Semantic Scholar
Full article: Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model
IJMS | Free Full-Text | Combination Effect of Cilengitide with Erlotinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition in Human Non-Small Cell Lung Cancer Cells
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. - Abstract - Europe PMC
8 Dose–response curves after treatment with cilengitide (CIL),... | Download Scientific Diagram
Cilengitide | C27H40N8O7 | CID 176873 - PubChem
Phase I & II Clinical Trials - Statistical Considerations - The University of Alabama at Birmingham
Integrin Inhibitor Cilengitide for the Treatment of Glioblastoma: A Brief Overview of Current Clinical Results | Anticancer Research
Cilengitide (EMD 121974) | ανβ3/ανβ5/α5β1 Inhibitor | MedChemExpress
Frontiers | Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Cilengitide
CIPSM - Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
Integrin Inhibitor Cilengitide for the Treatment of Glioblastoma: A Brief Overview of Current Clinical Results
Cilengitide trifluoroacetate | 99.8%(HPLC) | In Stock | Integrin inhibitor
Pharmaceutics | Free Full-Text | Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?
Frontiers | Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells
Frontiers | Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells
The Integrin Inhibitor Cilengitide and Bleomycin-Induced Pulmonary Fibrosis | SpringerLink
cilengitide | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Cilengitide (Merck) | Bioz | Ratings For Life-Science Research
Cilengitide inhibits metastatic bone colonization in a nude rat model
The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus | Cancer Gene Therapy
CILENGITIDE | New Drug Approvals
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma | Journal of Clinical Oncology
